Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?

IBTV speaks with industry leaders at ASGCT 2026 about new approaches to manufacturing, reimbursement, treatment delivery, and long-term value that could bring cell and gene therapies to more patients

  • September 11, 2026

  • 2 min

Share

  • 1

    Cell and gene therapies have the potential to transform serious diseases but face challenges in access due to high costs and complex delivery.

  • 2

    Industry leaders emphasize the need to reduce production costs and treat patients earlier to improve access to these therapies.

  • 3

    Expanding delivery beyond specialist centers is crucial for increasing patient access to cell and gene therapies.

  • 4

    Assessing the long-term value of therapies, rather than just their upfront costs, is essential for sustainable access.

  • 5

    Collaboration among manufacturers, regulators, healthcare systems, payers, and patient advocates is necessary for improving therapy accessibility.

Original Source(s)

Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?

  • September 11, 2026

Related Content

Robotic knee surgery put to the test

RACER-Knee compared Mako-assisted and conventional total knee replacement across 10 hospitals in Great Britain.

Pima Medical Institute Launches Dental Hygiene Program in Phoenix

New 18-month curriculum includes classroom, laboratory and clinical education for students pursuing associate degrees.

  • September 11, 2026

  • 3 min
Pediatric abscess incidence may be higher postpandemic

Head and neck abscess incidence was more than 3-fold higher following the pandemic, while patient characteristics and treatment patterns remained largely similar.